Gilead Sciences, Inc.
Pitch Summary: Gilead Sciences has demonstrated strong performance in its HIV franchise, particularly with the launch of Yeztugo, which has strengthened its market position. The company reported significant revenue growth from its key HIV drugs, including Biktarvy, and has seen promising sales figures for Yeztugo, which is expected to continue its upward trajectory. The approval […]
